Reserve your Exhibit Hall & Keynote Pass


  • 2,500 International Participants
  • Meet Face-to-Face with more than 170 Technology & Service Providers
  • Plenary Keynote Sessions
  • Networking Receptions
  • View 300 Research Posters on Display
  • Exhibit Hall Raffles


Monday, May 15 | 4:10 – 4:55pm

Carl-JunePLENARY PRESENTATION: Advances in CAR T Therapy
Carl June, MD, Richard W. Vague Professor in Immunotherapy; Professor of Medicine; Director, Center for Cellular Immunotherapies; Director, Parker Institute for Cancer Immunotherapy, University of Pennsylvania Perelman School of Medicine

Advances in the understanding of basic immunology have ushered in two major approaches for cancer therapy over the past 10 years. The first is checkpoint therapy to augment the function of the natural immune system. The second uses the emerging discipline of synthetic biology and the tools of molecular biology and genome engineering to create new forms of engineered cells with enhanced functionalities. The emergence of synthetic biology approaches for cellular engineering provides a broadly expanded set of tools for programming immune cells for enhanced function. Barriers to therapy of solid tumors will be discussed.



Monday, May 15
Exhibit Hall Open from 5:40 - 7:00pm

5:40 - 7:00pm Welcome Reception and Poster Viewing
6:30 - 7:00pm Young Scientist Meet Up

Tuesday, May 16
Exhibit Hall Open 10:30am - 4:30pm

10:30 - 11:10am Coffee Break and Poster Viewing
1:40 - 2:15pm Dessert Break and Poster Viewing
3:50 - 4:30pm Refreshment Break and Poster Viewing

Wednesday, May 17
Exhibit Hall Open 10:30am - 7:15pm

10:30 - 11:10am: Coffee Break and Poster Viewing
4:35 - 5:10pm: Ice Cream Break and Poster Viewing
4:45 - 5:05pm Speed Networking
6:40 - 7:40pm: Networking Reception
6:45pm Poster Award Winner Announced
6:50 - 7:20pm Women in Science Meet Up

Thursday, May 18
Exhibit Hall Open 10:00am - 1:15pm

10:00 - 10:40am: Coffee Break and Poster Viewing
12:10 - 1:15pm: Luncheon and Last Chance for Poster Viewing

**Exhibit hours are subject to change.**

Monday, May 15 | 4:55 - 5:40pm

John C. Marioni, PhDThe Next Frontier in Machine Learning and Biologics: "Lab in a Loop" Large Molecule Drug Discovery, From Optimization to de novo Discovery
John C. Marioni, PhD, Senior Vice President and Head of Computation, Research and Early Development, Genentech

A key opportunity in applying machine learning to augment biologic drug discovery and development is through constant iteration – a process we call "lab in a loop." By developing integrated methods for optimizing affinity and multiple developability parameters, as well as a close integration of antibody engineering, machine learning, and structural biology, we have the potential to more rapidly identify and test novel candidate molecules. Sophisticated machine learning frameworks allow us to integrate later stages of optimization into the earliest stages of discovery, while high-throughput experimental systems allow rapid improvement of all methods and molecules. This process starts with the integration of people and scientific culture and ends with tightly integrated computational and experimental systems.

Wednesday, May 17 | 11:30am – 12:15pm

Rebecca A. Sendak, PhDAdvancing Innovative Biologics Modalities from Research to Clinical Application – Novel Platforms, Automation, and Computation
Rebecca A. Sendak, PhD, Head, Global Large Molecules Research Platform, Sanofi

Addressing disease biology in the clinic with protein therapeutics has become increasingly complex. Turning to innovative and novel scaffolds offers opportunities to tailor therapeutics not previously possible due to advances in host cell engineering and protein design approaches. Designing and developing these modalities requires a next-generation approach as we exploit increased potential design space and also growing data sources to leverage as we invent the next wave of therapeutics.

Wednesday, May 17 | 12:15 – 1:00pm

Engineering Prime Editor Proteins for Therapeutic Applications

Andrew V. Anzalone, PhD, Director & Head, Prime Editing Platform, Scientific Co-Founder, Prime Medicine, Inc.

Precision gene editing technologies have the potential to address a wide range of genetic diseases. Prime Editing is a recently developed “search-and-replace” gene editing approach that can precisely perform a wide variety of DNA sequence edits at programmed target sites in human genomes without requiring double-strand DNA breaks or donor DNA templates. I will describe advances to prime editing technology that improve its efficiency, specificity, and capabilities for therapeutic applications.

Register Now

View By: